News

Expression of interest NTNU researchers - Horizon Europe calls 2025

Published on | 4 months ago

Programmes Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment Missions

The Norwegian University of Science and Technology (NTNU) has compiled a set of brochures, showcasing what NTNU's researchers can bring to the table on the topic of the six clusters within pillar II of the Horizon Europe programme. A seperate brochure covers the expertise NTNU can bring in the context of the 5 EU Missions. Through a mapping exercise, NTNU has matched their reserachers' interests in the upcoming Horizon Europe calls, based on both their experience and the industry relations they can bring to the bid. 

Interested to collaborate with NTNU? The NTNU Horizon Europe brochures are available here: Horizon Europe Mapping - NTNU

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1725 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.